Clinical trials

The following list shows the clinical trials currently open at the two sarcoma centres in London and the South East: University College London (UCLH) and The Royal Marsden (RMH). For further information please contact the research nurses at each site:

Last updated 30 May 2018

Name Description Type Centre Age
ANITA EORTC 1506 A Phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic nonoxazaphosporine-based first line chemotherapy for inoperable disease "ANITA" Phase II RMH 18+
AFATINIB FOR CHORDOMA A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma Phase II UCLH
ANNOUNCE 2 Phase 1b (Open Label)/Phase 2 (ONLY). Randomized, double-blinded study evaluating the efficacy of Gemcitabine and Docetaxel with or without a human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma (Academic) Phase II RMH
UCLH
18+
APPLE Phase I: Avelumab and hyPofractionated PalLiatve radiotherapy in metastatic soft-tissuE sarcoma Phase I RMH
BLU-285-1303 An international, multi-centre, open-label, randomised, phase III study of BLU-285 vs Regorafenib in patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) Phase III RMH
Chemotherapy and HRQoL in advanced STS Assessing the Impact of Chemotherapy on Health-Related Quality of Life (HRQoL) in Patients with Advanced Soft Tissue Sarcomas (STS) QoL study RMH 18+
ESPRIT ESP1/SARC025 Global Collaboration: A phase I study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma. Phase I UCLH CRF ≥ 13 years
Euro-Ewing 2012 International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours. Phase III RMH
UCLH
>2 years and < 50 years
EZH2 A phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma and Epitheliod type. Phase II RMH, UCLH 18+
GEMMK A phase I study to assess the safety and tolerability of MK-3475 in combination with fixed rate gemcitabine chemotherapy in patients with leioyosarcoma Phase I RMH 18+
HGUS-EORTC 62113 A randomized double-blind phase II study evaluating the role of maintenance cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) or response to doxorubicin +/- ifosfamide or in metastatic first line treatment. Phase II RMH
UCLH
18 years+
HOPE Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma. Phase I/II UCLH CRF 2 years to < 18 years (≤ 25 years for osteosarcoma subjects)
IMRIS A phase II study of intensity modulated radiotherapy (IMRT) in primary bone (STS cohort closed) Phase II UCLH 16+
INVICTUS Phase III, INterVentional, double-blind, placebo-controlled study to assess the safety and efficacy of DCC-2618 in patients with advanced c-KIT/PDGFRA gastrointestinal stromal TUmorS who have received prior treatment with Imatinib, Sunitinib, and/or Regorafenib Phase III RMH
KCP-330-020 (SEAL) A phase II/III multicentre, randomised, double-blind study of Selinexor (KPT - 330) verus placebo in patient with advanced unresectable differentiated liposarcoma Phase II/III RMH, UCLH
KINDRED The International Sarcoma Kindred Study: a global multi‐site prospective cancer genetics study. Translational RMH
UCLH
18+
PROSPECTUS PROgnoStic and PrEdiCTive ImmUnoprofiling of Sarcomas (PROSPECTUS) Retrospective TR study RMH
RAPPER Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy. Translational UCLH 16+
REECUr International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory ewing sarcoma. Phase II/III RMH
UCLH
>4 years and < 50 years
SSG XXII A phase III prospective, multi-centre, open-label, 2 arm study for evaluation of 2 durations of adjuvant treatment with the tyrosine kinase inhibitor imastinib mesylate of operable gastrointestinal stromal cells tumour (GIST) with a high risk for recurrence. Phase III RMH
UCLH
18+
TAPPAS (105SAR301) A randomised phase III trial of TRC105 and Pazopanib versus Pazopanib alone in patients with advanced angiosarcoma (TAPPAS)
Randomised 1:1
Phase III RMH 18+